The use of antithrombotic therapy for the prevention of pregnancy complications in women with thrombophilia continues to increase, despite a paucity of supportive data, as patients and their physicians are willing to try unproven interventions in an effort to achieve a successful pregnancy. Although these interventions are generally safe, they are costly and not entirely benign. If LMWH is used liberally in this setting, we may be intervening unnecessarily and exposing women to potentially serious side effects. This therapy is also costly and inconvenient. Therefore, there continues to be an urgent need for methodologically strong studies of sufficient sample size to determine the best treatment for thrombophilic women with a history of pregnancy complications.
Expert Rev Hematol. 2013;6(3):287-300. © 2013 Expert Reviews Ltd.